ReviewCardiovascular & hematological disorders drug targets2026
Marine-derived Bioactives as Novel Interventions for Cardiovascular Disorders.
Review in Cardiovascular & hematological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, affecting the heart, vasculature, pulmonary circulation, and cerebrovascular functions. Bioactive compounds from natural sources, particularly marine organisms, are gaining attention for their antioxidant, anti-inflammatory, and cardioprotective effects, offering safer alternatives to synthetic drugs.
methodsThis narrative review collated and critically analyzed peer-reviewed literature from the past two decades on marine-derived bioactive compounds with potential cardiovascular benefits. Key databases, including PubMed, Scopus, and Web of Science, were searched for studies describing chemical characterization, pharmacological activities, and mechanistic insights.
resultsMarine ecosystems provide diverse bioactives such as polysaccharides, polyphenols, carotenoids, peptides, proteins, and essential fatty acids. Compounds including exopolysaccharides, sulfated polysaccharides, phlorotannins, eicosapentaenoic acid, saringosterol, alginate, β- cryptoxanthin, macrolactin A, astaxanthin, and echinochrome A demonstrated significant antioxidant, lipid-lowering, anti-inflammatory, and vascular-protective actions in preclinical models. Several agents, such as omega-3-acid ethyl esters, have advanced to clinical use or late-stage trials for CVD prevention and management. DISCUSSION: The natural origin, structural diversity, and favorable safety profiles of these marine compounds underscore their promise as cardioprotective therapeutics. However, variability in extraction methods, limited human trials, and potential ecological constraints highlight the need for standardized protocols and sustainability assessments. Translational research must bridge the gap between experimental findings and clinical application.
conclusionMarine-derived bioactive compounds represent a rich, underexplored resource for novel interventions against cardiovascular disorders. Rigorous clinical validation and sustainable harvesting strategies are essential to fully realize their therapeutic potential.
Indexed as
Identifiers
41941296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.